Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: Together with chemotherapy, to the treatment of Grownup patients with locally recurrent unresectable or metastatic triple-negative breast cancer who have not obtained prior chemotherapy for metastatic disorder and whose tumours Specific programmed cell Dying-ligand one (mixed favourable rating ≥ 10) as det... https://aaronv553jid0.buyoutblog.com/profile